DX
Disease Management, Mechanisms, and Treatment (Platform/Oral)

Friday, May 29, 2015: 2:00 PM-4:00 PM
White River F
2:00 PM
The Effect of Daclizumab High-Yield Process (DAC HYP) on Patient-Centered Functional Outcomes: Results from the DECIDE Study
Michael Kaufman, MD, Cole Neurological Institute, University of Tennessee - Knoxville; Ludwig Kappos, MD, University Hospital Basel; Krzysztof W Selmaj, MD, PhD, Medical University of Lodz; Douglas L Arnold, MD, Montreal Neurological Institute, McGill University; Eva Havrdova, MD, Charles University in Prague; Alexey Boyko, MD, Moscow Multiple Sclerosis Center; Heinz Wiendl, MD, University of Münster; John Rose, MD, Department of Neurology University of Utah and Neurovirology Research Laboratory VASLCHCS, Imaging and Neuroscience Center; Steven J Greenberg, MD, AbbVie Biotherapeutics Inc.; Marianne T. Sweetser, MD, PhD, Biogen Idec, Inc.; Wei Ma, PhD, Biogen Idec, Inc.; Ping Wang, PhD, Biogen Idec, Inc.; Mark Beatty, MD, Biogen Idec

2:20 PM
Current Marijuana Usage By MS Status and Disability in the Narcoms Registry
Stacey S Cofield, PhD, University of Alabama at Birmingham; Amber R Salter, MPH, University of Alabama at Birmingham; Tuula Tyry, PhD, St. Joseph's Hospital and Medical Center; Sandre McNeal, MS, University of Alabama at Birmingham; Gary Cutter, PhD, University of Alabama at Birmingham; Ruth Ann Marrie, MD, PhD, FRCPC, University of Manitoba; Robert J. Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic

2:40 PM
Alemtuzumab (ALE) Improves Disability after Switch from Other Disease Modifying Therapies in a High Disability Treatment-Refractory Relapsing MS Cohort
Samuel F. Hunter, MD, PhD, NeuroNexus Center - Novel Pharmaceutics Institute; Isabelle St Clare-Hunter, BS, NeuroNexus Center - Novel Pharmaceutics Institute; Justin M Amburgey, BS, Advanced Neurosciences Institute; Gregory J Dick, BA, Advanced Neurosciences Institute; Kristen B Sherman, MS, PA-C, Advanced Neurosciences Institute; Madelyn B Rarick, BSN, Advanced Neurosciences Institute; Daniel Kantor, MD, NeuroNexus Center - Novel Pharmaceutics Institute

3:00 PM
Durable Effect of Alemtuzumab on MRI Activity and Brain Atrophy in Relapsing-Remitting Multiple Sclerosis Patients: 4-Year Follow-up of Care-MS II
Anthony Traboulsee, MD, The University of British Columbia; Hans-Peter Hartung, MD, Heinrich-Heine University; Eva Havrdova, MD, PhD, First Faculty of Medicine, Charles University in Prague; Krzysztof W Selmaj, MD, PhD, Medical University of Lodz; D Alastair S Compston, MD, University of Cambridge School of Clinical Medicine; David H Margolin, MD, PhD, Genzyme, a Sanofi company; Linda Kasten, MA, PROMETRIKA, LLC; Douglas L Arnold, MD, NeuroRx Research

3:20 PM
Increased Apolipoprotein A-I levels improve clinical and biological markers in EAE
Lidia Gardner, PhD, MBA, University of Tennessee HSC; Michael Levin, MD, University of Tennessee HSC

See more of: Platform